ClinicalTrials.gg
Sign In

Drug

Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 clinical trials

Also written TQB2102.

studies test it
16
open now
13
in phase 3
5
first study started
2022

Keep track of what changes. Save the Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

TQB2102 for injection
8
TQB2102 Injection
3

Development codes

TQB2102
2

Combined with it in one product

TQB2930 injection+TQB2102 for injection
1
TQB2102 with TQB2868
1
TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy
1
TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy
1
TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy
1

Studies by the year they started

16 studies that test it; most in 2024 (5)

Studies that test Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102, by start year
YearStudies
20221
20233
20245
20255
20262

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
9
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it.

Breast Neoplasms
6
Triple Negative Breast Neoplasms
2
Biliary Tract Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1

Who runs them

Industry 13 · Other 3

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (12) · Fudan University (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Henan Cancer Hospital (1)

Often tested with

Tested in the same studies.

Trastuzumab rezetecan (2) · Camrelizumab (2) · Famitinib (2) · Benmelstobart (2) · Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 (2) · Trifluridine tipiracil drug combination (1) · Anti-HER2 Bispecific Antibody TQB2930 (1) · Dalpiciclib (1)

Studies

Open first, then newest update. How each study uses Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 is read from its arms, and is right about nine times in ten.

Testing it · 16